| Year |
Citation |
Score |
| 2023 |
Papp S, Tombor L, Kakuszi B, Réthelyi JM, Bitter I, Czobor P. Electrophysiological underpinnings of dysfunctional inhibitory control in adults with attention-deficit/hyperactivity disorder: evidence for reduced NoGo anteriorization. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 37131048 DOI: 10.1007/s00702-023-02639-0 |
0.335 |
|
| 2020 |
Papp S, Tombor L, Kakuszi B, Balogh L, Réthelyi JM, Bitter I, Czobor P. Impaired early information processing in adult ADHD: a high-density ERP study. Bmc Psychiatry. 20: 292. PMID 32522183 DOI: 10.1186/S12888-020-02706-W |
0.387 |
|
| 2020 |
Baradits M, Bitter I, Czobor P. Multivariate patterns of EEG microstate parameters and their role in the discrimination of patients with schizophrenia from healthy controls. Psychiatry Research. 288: 112938. PMID 32315875 DOI: 10.1016/J.Psychres.2020.112938 |
0.345 |
|
| 2020 |
Kakuszi B, Szuromi B, Bitter I, Czobor P. Attention deficit hyperactivity disorder: Last in, first out - delayed brain maturation with an accelerated decline? European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 34: 65-75. PMID 32279924 DOI: 10.1016/J.Euroneuro.2020.03.011 |
0.386 |
|
| 2020 |
Arteaga-Henríquez G, Rosales-Ortiz SK, Arias-Vásquez A, Bitter I, Ginsberg Y, Ibañez-Jimenez P, Kilencz T, Lavebratt C, Matura S, Reif A, Rethelyi J, Richarte V, Rommelse N, Siegl A, Ramos-Quiroga JA. Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial. Trials. 21: 161. PMID 32046750 DOI: 10.1186/S13063-019-4040-X |
0.354 |
|
| 2020 |
Bugarski-Kirola D, Nunez R, Odetalla R, Bari MA, Bitter I, Feldman PD, (Cathy) Liu I, Stankovic S. T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT Schizophrenia Bulletin. 46: S247-S247. DOI: 10.1093/Schbul/Sbaa029.601 |
0.367 |
|
| 2019 |
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 31255396 DOI: 10.1016/J.Euroneuro.2019.06.008 |
0.432 |
|
| 2019 |
Mucci A, Vignapiano A, Bitter I, Austin SF, Delouche C, Dollfus S, Erfurth A, Fleischhacker WW, Giordano GM, Gladyshev I, Glenthøj B, Gütter K, Hofer A, Hubeňák J, Kaiser S, et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 31255394 DOI: 10.1016/J.Euroneuro.2019.05.006 |
0.407 |
|
| 2019 |
Bitter I, Mohr P, Balogh L, Látalová K, Kakuszi B, Stopková P, Zmeškalová-Jelenová D, Pulay A, Czobor P. ADHD: a hidden comorbidity in adult psychiatric patients. Attention Deficit and Hyperactivity Disorders. 11: 83-89. PMID 30927233 DOI: 10.1007/S12402-019-00285-9 |
0.451 |
|
| 2019 |
Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, Delsol C, Barthe L, Brunner V, Fabre C, Fagard M, Montagne A, Tonner F. Randomized, double-blind, placebo-controlled study of F17464, a preferential D antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30822774 DOI: 10.1038/S41386-019-0355-2 |
0.35 |
|
| 2019 |
Vokó Z, Bitter I, Merisch B, Réthelyi J, Molnar A, Pitter J, Gotze A, Ruzsa V, Koczian K, Fonticoli L, Lelli F, Nemeth B. PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE Value in Health. 22: S814-S815. DOI: 10.1016/J.Jval.2019.09.2203 |
0.353 |
|
| 2018 |
Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas Brugué M, Bobes J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry : the Journal of the Association of European Psychiatrists. 56: 14-34. PMID 30453134 DOI: 10.1016/J.Eurpsy.2018.11.001 |
0.437 |
|
| 2018 |
Stein DJ, Khoo JP, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C, Bauer M, Bitter I, Mosolov SN, Olivier V, Matharan S, Picarel-Blanchot F, de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 28: 970-979. PMID 30135032 DOI: 10.1016/J.Euroneuro.2018.05.006 |
0.343 |
|
| 2018 |
Kakuszi B, Bitter I, Czobor P. Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. Comprehensive Psychiatry. 85: 23-29. PMID 29957374 DOI: 10.1016/J.Comppsych.2018.06.003 |
0.363 |
|
| 2018 |
Baradits M, Kakuszi B, Bálint S, Fullajtár M, Mód L, Bitter I, Czobor P. Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. European Archives of Psychiatry and Clinical Neuroscience. PMID 29569047 DOI: 10.1007/S00406-018-0889-Z |
0.325 |
|
| 2018 |
Tombor L, Kakuszi B, Papp S, Réthelyi J, Bitter I, Czobor P. Decreased resting gamma activity in adult Attention Deficit/Hyperactivity Disorder. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-33. PMID 29457912 DOI: 10.1080/15622975.2018.1441547 |
0.388 |
|
| 2018 |
Németh B, Fasseeh A, Molnár A, Bitter I, Horváth M, Kóczián K, Götze Á, Nagy B. A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research. 1-9. PMID 29347854 DOI: 10.1080/14737167.2018.1430571 |
0.323 |
|
| 2018 |
Hegerl U, Mergl R, Sander C, Dietzel J, Bitter I, Demyttenaere K, Gusmão R, Arrillaga AG, Zorrilla I, Alocén AG, Sola VP, Vieta E, Juckel G, Zimmermann US, Bauer M, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 28: 185-194. PMID 29174864 DOI: 10.1016/J.Euroneuro.2017.11.003 |
0.395 |
|
| 2017 |
Balogh L, Kakuszi B, Papp S, Tombor L, Bitter I, Czobor P. Neural Correlates of Error Monitoring in Adult Attention Deficit Hyperactivity Disorder After Failed Inhibition in an Emotional Go/No-Go Task. The Journal of Neuropsychiatry and Clinical Neurosciences. appineuropsych161001. PMID 28464703 DOI: 10.1176/Appi.Neuropsych.16100183 |
0.381 |
|
| 2017 |
Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. Potential role of patients' CYP3A-status in clozapine pharmacokinetics. The International Journal of Neuropsychopharmacology. PMID 28340122 DOI: 10.1093/Ijnp/Pyx019 |
0.321 |
|
| 2017 |
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England). PMID 28185672 DOI: 10.1016/S0140-6736(17)30060-0 |
0.428 |
|
| 2017 |
Bitter I, Groc M, Delsol C, Fabre C, Fagard M, Barthe L, Gaudoux F, Brunner V, Brackman F, Tonner F. Efficacy of F17464, a new preferential D3 antagonist in a placebo-controlled phase 2 study of patients with an acute exacerbation of schizophrenia European Psychiatry. 41: S387-S387. DOI: 10.1016/J.Eurpsy.2017.02.428 |
0.307 |
|
| 2016 |
Czobor P, Kakuszi B, Németh K, Balogh L, Papp S, Tombor L, Bitter I. Electrophysiological indices of aberrant error-processing in adults with ADHD: a new region of interest. Brain Imaging and Behavior. PMID 27752922 DOI: 10.1007/S11682-016-9610-X |
0.343 |
|
| 2016 |
Kakuszi B, Tombor L, Papp S, Bitter I, Czobor P. Altered response-preparation in patients with adult ADHD: A high-density ERP study. Psychiatry Research. 249: 57-66. PMID 27000308 DOI: 10.1016/J.Pscychresns.2016.02.008 |
0.395 |
|
| 2016 |
Marder S, Laszlovszky I, Szalai E, Szatmári B, Harsányi J, Barabássy A, Debelle M, Durgam S, Bitter I, Németh G. Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)31595-4 |
0.391 |
|
| 2016 |
Baradits M, Bálint S, Kakuszi B, Bitter I, Czobor P. Gamma band activity in spontaneous EEG in patients with schizophrenia European Neuropsychopharmacology. 26: S344-S345. DOI: 10.1016/S0924-977X(16)31271-8 |
0.311 |
|
| 2016 |
Balint S, Baradits M, Kakuszi B, Bitter I, Czobor P. Relationship between cognitive flexibility and symptom presentation in adult ADHD European Neuropsychopharmacology. 26: S344. DOI: 10.1016/S0924-977X(16)31270-6 |
0.396 |
|
| 2016 |
Németh G, Debelle M, Laszlovszky I, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Durgam S, Bitter I, Galderisi S. Monotherapy treatment with cariprazine for the treatment of predominant negative symptoms of patients with schizophrenia: A double-blind, active comparator-controlled trial European Psychiatry. 33: s256-s257. DOI: 10.1016/J.Eurpsy.2016.01.652 |
0.4 |
|
| 2016 |
Pulay AJ, Bitter I, Papp S, Gulácsi L, Péntek M, Brodszky V, Hevér NV, Rencz F, Baji P. Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD) Applied Research in Quality of Life. 1-16. DOI: 10.1007/S11482-016-9467-6 |
0.376 |
|
| 2015 |
Bitter I, Fehér L, Tényi T, Czobor P. Treatment adherence and insight in schizophrenia Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 30: 18-26. PMID 25867885 |
0.304 |
|
| 2014 |
Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophrenia Research. 152: 246-54. PMID 24275583 DOI: 10.1016/J.Schres.2013.10.034 |
0.372 |
|
| 2014 |
Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietiläinen OP, Lin K, Papiol S, Huttenlocher J, Sigurdsson E, Vassos E, Giegling I, Breuer R, Fraser G, ... ... Bitter I, et al. Common variant at 16p11.2 conferring risk of psychosis. Molecular Psychiatry. 19: 108-14. PMID 23164818 DOI: 10.1038/Mp.2012.157 |
0.345 |
|
| 2014 |
Bitter I. EPA-1434 - Antipsychotics European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78634-1 |
0.31 |
|
| 2014 |
Bitter I, Czobor P. EPA-1421 – Progress in the selection and delivery of pharmacological treatments in psychiatry European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78623-7 |
0.303 |
|
| 2014 |
Czobor P, Kakuszi B, Tombor L, Papp S, Balogh L, Bitter I. EPA-0649 – Response inhibition in attention deficit hyperactivity disorder (ADHD): the influence of emotional-valence on the P300 brain potential European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78021-6 |
0.387 |
|
| 2014 |
Kakuszi B, Papp S, Tombor L, Balogh L, Bitter I, Czobor P. EPA-0645 – Neural correlates of impairments in conflict monitoring in ADHD: an event related potential (ERP) study European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78019-8 |
0.41 |
|
| 2013 |
Komlósi S, Csukly G, Stefanics G, Czigler I, Bitter I, Czobor P. Fearful face recognition in schizophrenia: An electrophysiological study Schizophrenia Research. 149: 135-140. PMID 23870809 DOI: 10.1016/J.Schres.2013.06.044 |
0.313 |
|
| 2013 |
Szuromi B, Bitter I, Czobor P. Functional impairment in adults positively screened for attention-deficit hyperactivity disorder: The role of symptom presentation and executive functioning Comprehensive Psychiatry. 54: 974-981. PMID 23684546 DOI: 10.1016/J.Comppsych.2013.04.002 |
0.461 |
|
| 2013 |
Réthelyi JM, Benkovits J, Bitter I. Genes and environments in schizophrenia: The different pieces of a manifold puzzle Neuroscience and Biobehavioral Reviews. 37: 2424-2437. PMID 23628741 DOI: 10.1016/J.Neubiorev.2013.04.010 |
0.319 |
|
| 2013 |
Bitter I, Katona L, Zámbori J, Takács P, Fehér L, Diels J, Bacskai M, Lang Z, Gyáni G, Czobor P. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1383-90. PMID 23477752 DOI: 10.1016/J.Euroneuro.2013.02.003 |
0.303 |
|
| 2013 |
Kluge M, Hegerl U, Sander C, Dietzel J, Mergl R, Bitter I, Demyttenaere K, Gusmão R, Gonzalez-Pinto A, Perez-Sola V, Vieta E, Juckel G, Zimmermann US, Bauer M, Sienaert P, et al. Methylphenidate in mania project (MEMAP): Study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate Bmc Psychiatry. 13. PMID 23446109 DOI: 10.1186/1471-244X-13-71 |
0.347 |
|
| 2013 |
Czobor P, Volavka J, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW. Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology. 33: 258-61. PMID 23422388 DOI: 10.1097/Jcp.0B013E3182856886 |
0.345 |
|
| 2013 |
Simon V, Czobor P, Bitter I. Is ADHD severity in adults associated with the lifetime prevalence of comorbid depressive episodes and anxiety disorders? European Psychiatry. 28: 308-314. PMID 22986127 DOI: 10.1016/J.Eurpsy.2012.05.002 |
0.752 |
|
| 2013 |
Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 196-204. PMID 22647933 DOI: 10.1016/J.Euroneuro.2012.04.019 |
0.427 |
|
| 2012 |
Bitter I, Kurimay T. State of psychiatry in Hungary International Review of Psychiatry. 24: 307-313. PMID 22950769 DOI: 10.3109/09540261.2012.694856 |
0.304 |
|
| 2012 |
Bitter I, Angyalosi A, Czobor P. Pharmacological treatment of adult ADHD Current Opinion in Psychiatry. 25: 529-534. PMID 22801362 DOI: 10.1097/Yco.0B013E328356F87F |
0.43 |
|
| 2012 |
Vassos E, Steinberg S, Cichon S, Breen G, Sigurdsson E, Andreassen OA, Djurovic S, Morken G, Grigoroiu-Serbanescu M, Diaconu CC, Czerski PM, Hauser J, Babadjanova G, Abramova LI, Mühleisen TW, ... ... Bitter I, et al. Replication study and meta-analysis in European samples supports association of the 3p21.1 locus with bipolar disorder. Biological Psychiatry. 72: 645-50. PMID 22560537 DOI: 10.1016/J.Biopsych.2012.02.040 |
0.337 |
|
| 2012 |
Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry : the Journal of the Association of European Psychiatrists. 27: 114-28. PMID 22119161 DOI: 10.1016/J.Eurpsy.2011.08.002 |
0.317 |
|
| 2012 |
Réthelyi JM, Czobor P, Polgár P, Mersich B, Bálint S, Jekkel E, Magyar K, Mészáros A, Fábián A, Bitter I. General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 262: 107-15. PMID 21792534 DOI: 10.1007/S00406-011-0224-4 |
0.365 |
|
| 2012 |
Komlósi S, Csukly G, Stefanics G, Czigler I, Czobor P, Bitter I. AS19-02 - Electrophysiological correlates of impaired facial emotion recognition European Psychiatry. 27: 1. DOI: 10.1016/S0924-9338(12)74005-1 |
0.333 |
|
| 2012 |
Péntek M, Gulácsi L, V. Hevér N, Papp S, Baji P, Brodszky V, Pulay A, Balogh O, Bitter I. PMH35 EQ-5D Utilities and Productivity of Adults With Attention-Deficit/Hyperactivity Disorder: Review of the Literature and a Cross-Sectional Survey in Hungary Value in Health. 15: A340. DOI: 10.1016/J.Jval.2012.08.825 |
0.358 |
|
| 2011 |
Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). The Journal of Clinical Psychiatry. 72: 955-61. PMID 21824456 DOI: 10.4088/Jcp.10M06529 |
0.39 |
|
| 2011 |
Szuromi B, Czobor P, Komlósi S, Bitter I. P300 deficits in adults with attention deficit hyperactivity disorder: A meta-analysis Psychological Medicine. 41: 1529-1538. PMID 20961477 DOI: 10.1017/S0033291710001996 |
0.398 |
|
| 2011 |
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OP, ... ... Bitter I, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Molecular Psychiatry. 16: 59-66. PMID 20048749 DOI: 10.1038/Mp.2009.149 |
0.376 |
|
| 2011 |
Bitter I. The assessment of self experiences in patients with primary negative symptoms European Psychiatry. 26: 2071-2071. DOI: 10.1016/S0924-9338(11)73774-9 |
0.401 |
|
| 2011 |
Benkovits J, Polgár P, Fábián Á, Czobor P, Bitter I, Réthelyi J. The effect of DTNBP1 and comt risk variants and comorbid drug-abuse in patients with schizophrenia: A Gene-Environment Interaction? European Psychiatry. 26: 1345-1345. DOI: 10.1016/S0924-9338(11)73050-4 |
0.351 |
|
| 2011 |
Réthelyi J, Polgár P, Benkovits J, Jekkel É, Czobor P, Bitter I. The association of NRG1, DTNBP1, RGS4, G72/G30 and PIP5K2A candidate genes with cognition in patients with schizophrenia and healthy controls European Psychiatry. 26: 811-811. DOI: 10.1016/S0924-9338(11)72516-0 |
0.355 |
|
| 2011 |
Farkas K, Réthelyi J, Polgár P, Benkovits J, Fábián Á, Czobor P, Bitter I. BDNF and DISC1 are associated with cognitive dysfunction but not with schizophrenia in a hungarian sample European Psychiatry. 26: 805-805. DOI: 10.1016/S0924-9338(11)72510-X |
0.387 |
|
| 2011 |
Stein D, Ahokas A, Allgulander C, Soegaard J, Bitter I, Lehtmets A, Wahlstedt K, Van Amerigen M. Long-term treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months European Psychiatry. 26: 181-181. DOI: 10.1016/S0924-9338(11)71892-2 |
0.36 |
|
| 2010 |
Inczédy-Farkas G, Benkovits J, Balogh N, Almos P, Scholtz B, Zahuczky G, Török Z, Nagy K, Réthelyi J, Makkos Z, Kassai-Farkas A, Egerházy A, Tuzko J, Janka Z, Bitter I, et al. [SCHIZOBANK - The Hungarian national schizophrenia biobank and its role in schizophrenia research and in personalized medicine]. Orvosi Hetilap. 151: 1403-8. PMID 20719713 DOI: 10.1556/Oh.2010.28943 |
0.362 |
|
| 2010 |
Polgár P, Réthelyi JM, Bálint S, Komlósi S, Czobor P, Bitter I. Executive function in deficit schizophrenia: What do the dimensions of the Wisconsin Card Sorting Test tell us? Schizophrenia Research. 122: 85-93. PMID 20627227 DOI: 10.1016/J.Schres.2010.06.007 |
0.41 |
|
| 2010 |
Réthelyi JM, Bakker SC, Polgár P, Czobor P, Strengman E, Pásztor PI, Kahn RS, Bitter I. Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 792-801. PMID 19937977 DOI: 10.1002/Ajmg.B.31049 |
0.399 |
|
| 2010 |
Bitter I, Simon V, Bálint S, Mészáros A, Czobor P. How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample European Archives of Psychiatry and Clinical Neuroscience. 260: 287-296. PMID 19806424 DOI: 10.1007/S00406-009-0076-3 |
0.742 |
|
| 2010 |
Szuromi B, Czorbor P, Komlósi S, Bitter I. Meta-analysis of target-related P300 characteristics in adults with attention-deficit/hyperactivity disorder (ADHD): Relevance of target probability International Journal of Psychophysiology. 77: 248-249. DOI: 10.1016/J.Ijpsycho.2010.06.057 |
0.396 |
|
| 2009 |
Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): A meta-analysis International Journal of Neuropsychopharmacology. 12: 1137-1147. PMID 19580697 DOI: 10.1017/S1461145709990198 |
0.736 |
|
| 2009 |
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, ... ... Bitter I, et al. Common variants conferring risk of schizophrenia. Nature. 460: 744-7. PMID 19571808 DOI: 10.1038/Nature08186 |
0.35 |
|
| 2009 |
Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis British Journal of Psychiatry. 194: 204-211. PMID 19252145 DOI: 10.1192/Bjp.Bp.107.048827 |
0.736 |
|
| 2009 |
Bálint S, Czobor P, Komlósi S, Mészáros A, Simon V, Bitter I. Attention deficit hyperactivity disorder (ADHD): Gender- and age-related differences in neurocognition Psychological Medicine. 39: 1337-1345. PMID 18713489 DOI: 10.1017/S0033291708004236 |
0.743 |
|
| 2009 |
Polgar P, Bitter I, Keri S, Czobor P. P.3.a.022 Executive function in deficit schizophrenia European Neuropsychopharmacology. 19: S492-S493. DOI: 10.1016/S0924-977X(09)70777-1 |
0.368 |
|
| 2009 |
Bitter I. What will be the Consequences from the Changes in ICD-11/DSM-V for Decision Making in Clinical Psychopharmacotherapy? European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)70329-3 |
0.347 |
|
| 2008 |
Bálint S, Czobor P, Mészáros A, Simon V, Bitter I. Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review | A felnottkori figyelemhiányos/hiperaktivitás-zavarban tapasztalható neuropszichológial deficit: irodalmi áttekintés Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 23: 324-335. PMID 19129549 |
0.74 |
|
| 2008 |
Baran B, Bitter I, Ungvari GS, Nagy Z, Gazdag G. The beginnings of modern psychiatric treatment in Europe. Lessons from an early account of convulsive therapy. European Archives of Psychiatry and Clinical Neuroscience. 258: 434-40. PMID 18504632 DOI: 10.1007/S00406-008-0816-9 |
0.303 |
|
| 2008 |
Farkas M, Polgár P, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. Associative learning in deficit and nondeficit schizophrenia. Neuroreport. 19: 55-8. PMID 18281892 DOI: 10.1097/Wnr.0B013E3282F2Dff6 |
0.75 |
|
| 2008 |
Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study European Neuropsychopharmacology. 18: 170-180. PMID 17884390 DOI: 10.1016/J.Euroneuro.2007.08.001 |
0.738 |
|
| 2008 |
Polgár P, Farkas M, Nagy O, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophrenia Research. 99: 200-7. PMID 17693060 DOI: 10.1016/J.Schres.2007.06.027 |
0.746 |
|
| 2008 |
Czobor P, Komlosi S, Bitter I. Placebo-controlled clinical trials of new atypical antipsychotics in schizophrenia European Psychiatry. 23: S157. DOI: 10.1016/J.Eurpsy.2008.01.925 |
0.335 |
|
| 2007 |
Polgár P, Farkas M, Nagy O, Kelemen O, Réthelyi J, Bitter I, Myers CE, Gluck MA, Kéri S. [Learning cognitive skills in depression: the effect of context-change]. Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 271-5. PMID 18167422 |
0.734 |
|
| 2007 |
Mészáros A, Czobor P, Bálint S, Simon V, Bitter I. Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review | A felnottkori figyelemhiányos/hiperaktivitás zavar (ADHD) gyógyszeres kezelésének hatékonysága: irodalmi áttekintés Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 259-270. PMID 18167421 |
0.737 |
|
| 2007 |
Pethõ B, Tusnády G, Vargha A, Tolna J, Farkas M, Vizkeleti G, Tóth A, Szilágyi A, Bitter I, Kelemen A, Czobor P. Validity of reliability: comparison of interrater reliabilities of psychopathological symptoms. The Journal of Nervous and Mental Disease. 195: 606-13. PMID 17632252 DOI: 10.1097/Nmd.0B013E318093F45D |
0.735 |
|
| 2007 |
Simon V, Czobor P, Bálint S, Mészáros A, Murai Z, Bitter I. Detailed review of epidemiologic studies on adult Attention Deficit/Hyperactivity Disorder (ADHD) | A felnôttkori Figyelemhiányos/Hiperaktivitási Zavar (Attention Deficit/Hyperactivity Disorder--ADHD) epidemiológiai vizsgálatainak részletes áttekintése Psychiatria Hungarica : a Magyar PszichiáTriai TáRsasáG TudomáNyos FolyóIrata. 22: 4-19. PMID 17558040 |
0.726 |
|
| 2007 |
Kelemen O, Nagy O, Mátyássy A, Bitter I, Benedek G, Vidnyánszky Z, Kéri S. How well do patients with schizophrenia track multiple moving targets? Neuropsychology. 21: 319-25. PMID 17484595 DOI: 10.1037/0894-4105.21.3.319 |
0.347 |
|
| 2007 |
Meszaros A, Bitter I. The assessment of adherence using a questionnaire in patients suffering from schizophrenia European Psychiatry. 22: S104. DOI: 10.1016/J.Eurpsy.2007.01.328 |
0.354 |
|
| 2006 |
Treuer T, Anders M, Bitter I, Dobre G, Pecenak J, Dyachkova Y, Harrison G, O'Mahoney J. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). International Journal of Psychiatry in Clinical Practice. 10: 78-90. PMID 24940957 DOI: 10.1080/13651500500409663 |
0.406 |
|
| 2006 |
Jones RM, Thompson C, Bitter I. A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania. European Psychiatry : the Journal of the Association of European Psychiatrists. 21: 1-9. PMID 16487905 DOI: 10.1016/J.Eurpsy.2005.02.002 |
0.327 |
|
| 2005 |
Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: A prospective naturalistic study (IC-SOHO) European Psychiatry. 20: 403-408. PMID 16084068 DOI: 10.1016/J.Eurpsy.2005.01.009 |
0.372 |
|
| 2005 |
Bitter I, Basson BR, Dossenbach MR. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients International Clinical Psychopharmacology. 20: 19-21. PMID 15602111 DOI: 10.1097/00004850-200501000-00004 |
0.318 |
|
| 2004 |
Maciulis V, Bitter I, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Dossenbach M, Walker D. Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. Current Therapeutic Research, Clinical and Experimental. 65: 57-69. PMID 24936104 DOI: 10.1016/S0011-393X(04)90005-7 |
0.374 |
|
| 2004 |
Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 457-70. PMID 15589385 DOI: 10.1016/J.Euroneuro.2004.01.002 |
0.316 |
|
| 2004 |
Dossenbach M, Erol A, Kessaci MEM, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I. Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol Journal of Clinical Psychiatry. 65: 312-321. PMID 15096069 DOI: 10.4088/Jcp.V65N0305 |
0.425 |
|
| 2004 |
Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28: 173-80. PMID 14687871 DOI: 10.1016/J.Pnpbp.2003.09.033 |
0.398 |
|
| 2003 |
Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 48: 716-21. PMID 14733451 DOI: 10.1177/070674370304801102 |
0.328 |
|
| 2003 |
Balázs J, Lecrubier Y, Csiszér N, Koszták J, Bitter I. Prevalence and comorbidity of affective disorders in persons making suicide attempts in Hungary: Importance of the first depressive episodes and of bipolar II diagnoses Journal of Affective Disorders. 76: 113-119. PMID 12943940 DOI: 10.1016/S0165-0327(02)00084-8 |
0.315 |
|
| 2003 |
Kasper S, Lowry A, Hodge A, Bitter I, Dossenbach M. P.2.067 An analysis of tardive dyskinesia in intercontinental outpatients with schizophrenia European Neuropsychopharmacology. 13: S308. DOI: 10.1016/S0924-977X(03)92020-7 |
0.331 |
|
| 2003 |
Pečeňák J, Kaps P, Treuer T, Bitter I, Hodge A, Grigoriu A, Trzebiatowska I, Herman E, Peciukaitiene D, Smulevich S, Kökényes M. P.2.066 Effectiveness of antipsychotic treatments for patients from the Central Eastern Europe (CEE) region participating in the 3-year intercontinental schizophrenia outpatient health outcomes (IC-SOHO) observational study: 6-month results European Neuropsychopharmacology. 13: S307-S308. DOI: 10.1016/S0924-977X(03)92019-0 |
0.325 |
|
| 2003 |
Bitter I, Maciulis V, Milasiunas R, Dembinskas A, Radavicius L, Kaunas A, Walker D, Dossenbach M. Safety and efficacy of olanzapine in treating patients with schizophrenia Schizophrenia Research. 60: 273-274. DOI: 10.1016/S0920-9964(03)80432-2 |
0.339 |
|
| 2000 |
Balázs J, Bitter I, Lecrubier Y, Csiszér N, Ostorharics G. Prevalence of subthreshold forms of psychiatric disorders in persons making suicide attempts in Hungary. European Psychiatry : the Journal of the Association of European Psychiatrists. 15: 354-61. PMID 11004730 DOI: 10.1016/S0924-9338(00)00503-4 |
0.313 |
|
| 1999 |
Bitter I, Brook S, Dossenbach M, Janka Z, Banki C, Selemani S, Grundy S, Martenyi F. Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia European Neuropsychopharmacology. 9: 288. DOI: 10.1016/S0924-977X(99)80346-0 |
0.362 |
|
| 1992 |
Bitter I, Scheurer J, Volavka J. Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity???? Reply Journal of Clinical Psychopharmacology. 12: 65. DOI: 10.1097/00004714-199202000-00020 |
0.343 |
|
| 1992 |
Bitter I, Scheurer J, Volavka J. Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity?—Reply Current Opinion in Cardiology. 7: 65. DOI: 10.1097/00001573-199202000-00022 |
0.343 |
|
| 1991 |
Czobor P, Bitter I, Volavka J. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Research. 36: 129-39. PMID 2017528 DOI: 10.1016/0165-1781(91)90125-9 |
0.309 |
|
| 1990 |
Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Comprehensive Psychiatry. 31: 216-26. PMID 2340716 DOI: 10.1016/0010-440X(90)90005-D |
0.393 |
|
| 1989 |
Bitter I, Jaeger J, Volavka J, Cooper T. Failure of subjective complaints to respond to haloperidol in acute schizophrenia Schizophrenia Research. 2: 195. DOI: 10.1016/0920-9964(89)90231-4 |
0.314 |
|
| Show low-probability matches. |